Section Arrow
CRSP.NASDAQ
- CRISPR Therapeutics AG
Quotes are at least 15-min delayed:2026/04/26 18:55 EDT
Regular Hours
Last
 48.785
-6.395 (-11.59%)
Day High 
55.18 
Prev. Close
55.18 
1-M High
59.39 
Volume 
3.85M 
Bid
49.8
Ask
50.2
Day Low
48.77 
Open
55.01 
1-M Low
44.12 
Market Cap 
5.32B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 55.82 
20-SMA 52.2 
50-SMA 52.57 
52-W High 78.48 
52-W Low 33.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.47/-5.60
Enterprise Value
5.51B
Balance Sheet
Book Value Per Share
19.93
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
1.76
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCNIScinai Immunotherapeutics Ltd.0.737+0.281+61.62%0.15PE
ENVBEnveric Biosciences Inc.5.04+1.02+25.37%0PE
SGMOSangamo Therapeutics0.1901-0.0649-25.45%-- 
LNAILunai Bioworks Inc.0.3101+0.0054+1.77%-- 
IBRXImmunityBio7.44-0.75-9.16%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.